Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial-Reference-Cited by-同舟云学术

Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial

Published:2023-12 Issue:12 Volume:143 Page:2378-2385.e7
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Pandya Rachita^ORCID,Dan Joshua^ORCID,Kleitsch Julianne^ORCID,White Barbara^ORCID,Werth Victoria P.^ORCID

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference24 articles.

1. Trial of intravenous immune globulin in dermatomyositis;Aggarwal;N Engl J Med,2022

2. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis

3. The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review;Ahmed;Semin Arthritis Rheum,2020

4. Validation of the cutaneous dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change;Anyanwu;Br J Dermatol,2015

5. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota;Bendewald;Arch Dermatol,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-up Data from a Three-year Open-Label Extension Study;JID Innovations;2024-09

2. Clinical endpoints in myositis: challenges and ways forward;Current Opinion in Rheumatology;2024-08-23

3. Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review;Experimental Dermatology;2024-03

4. Current myositis clinical trials and tribulations;Annals of the Rheumatic Diseases;2024-01-12

5. Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives;Annals of Dermatology;2024